There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech
Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza
vaccine, Inflexal V. Since 1992, 29 company sponsored clinical studies investigating
the efficacy and safety of Inflexal V have been completed in which 3920 subjects participated.
During its decade on the market, Inflexal V has shown an excellent tolerability profile
due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde
and its purity is reflected in the low ovalbumin content. By mimicking natural infection,
the vaccine is highly efficacious. Inflexal V is the only adjuvanted influenza vaccine
licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised
elderly, adults and children. This review presents and discusses the experience with
Inflexal V during the past decade.